Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Validating Stat3 in cancer therapy

James E Darnell

    Nature Medicine
    |June 7, 2005
    PubMed
    Summary

    No abstract available in PubMed .

    Related Experiment Videos

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    The JAK-STAT pathway at 30: Much learned, much more to do.

    Cell·2022
    Same author

    Pre-mRNA processing includes <i>N</i><sup>6</sup> methylation of adenosine residues that are retained in mRNA exons and the fallacy of "RNA epigenetics".

    RNA (New York, N.Y.)·2017
    Same author

    m<sup>6</sup>A mRNA modifications are deposited in nascent pre-mRNA and are not required for splicing but do specify cytoplasmic turnover.

    Genes & development·2017
    Same author

    Mutations in the linker domain affect phospho-STAT3 function and suggest targets for interrupting STAT3 activity.

    Proceedings of the National Academy of Sciences of the United States of America·2015
    Same author

    A majority of m6A residues are in the last exons, allowing the potential for 3' UTR regulation.

    Genes & development·2015
    Same author

    The JAK-STAT pathway at 20.

    JAK-STAT·2013
    Same journal

    Author Correction: Digital AVATAR therapy for distressing voices in psychosis: the phase 2/3 AVATAR2 trial.

    Nature medicine·2026
    Same journal

    Clinical decision support in hematological malignancies using a case-grounded AI agent.

    Nature medicine·2026
    Same journal

    Multi-antigen-targeting T cells in pediatric central nervous system tumors: a phase 1 trial.

    Nature medicine·2026
    Same journal

    Agents AMIE and MIRA advance medical AI capabilities.

    Nature medicine·2026
    Same journal

    Author Correction: SEZ6-targeting antibody-drug conjugate ABBV-706 in advanced small cell lung cancer and solid tumors: a phase 1 trial.

    Nature medicine·2026
    Same journal

    Delivering the benefits of genomic data reanalysis for diagnosis equitably and at scale.

    Nature medicine·2026
    See all related articles